RAS-targeting small molecules redefine pancreatic cancer treatment
PLOS Medicine ·
What to know
A Perspective in PLOS Medicine highlights that treatment for pancreatic adenocarcinoma is moving beyond cytotoxic chemotherapy, with recent advances in RAS-targeting small molecule inhibitors reshaping therapeutic paradigms. The authors discuss clinical trial results and the ongoing challenge of treatment resistance.
Source and evidence
PLOS MedicineOriginal language · und ·Original author: Samuel P. Soff, Eileen M. O’Reilly · PLOS Medicine Readzer provides an abridged translation. CC-BY-4.0.Source licence
Why it matters by industry
- Healthcare & Life Sciences
Directly relevant to oncology drug development and clinical practice, as it summarizes emerging RAS-targeted therapies for a difficult-to-treat cancer.
Reviewed summary. The complete article remains at its original source.